Quest Diagnostics (DGX) Tops Q4 EPS by 4c; offers guidance

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $2.23, $0.04 better than the analyst estimate of $2.19. Revenue for the quarter came in at $2.62 billion versus the consensus estimate of $2.58 billion.

GUIDANCE:

Quest Diagnostics sees FY2025 EPS of $9.55-$9.80, versus the consensus of $9.72. Quest Diagnostics sees FY2025 revenue of $10.7-10.85 billion, versus the consensus of $10.671 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Morgan Stanley Upgrades Dexerials Corp (4980:JP) to Overweight
• Irving Advances the Unoya Target at Its Shika Epithermal Au-Ag Project, Noto Peninsula, Honshu, Japan through Systematic Geological, Geochemical and Geophysical Work
• Goldgroup Announces Commitment for Strategic Investment in Luca Mining